{"organizations": [], "uuid": "acca97da0af9605b6b4b16045d23569569cfe1a1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/idUSL8N1SA1AK", "country": "US", "domain_rank": 408, "title": "Cellectis Submits Investigational New Drug Application To FDA For UCART22", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-03T14:11:00.000+03:00", "replies_count": 0, "uuid": "acca97da0af9605b6b4b16045d23569569cfe1a1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/idUSL8N1SA1AK", "ord_in_thread": 0, "title": "Cellectis Submits Investigational New Drug Application To FDA For UCART22", "locations": [], "entities": {"persons": [{"name": "talen", "sentiment": "none"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - CELLECTIS SA:\n* SAID ON WEDNESDAY IT HAS SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE US FDA REQUESTING APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCART22\n* UCART22 IS CO’S SECOND WHOLLY CONTROLLED TALEN® GENE-EDITED PRODUCT CANDIDATE FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN ADULT PATIENTS\n* PENDING REGULATORY CLEARANCE, CELLECTIS PLANS TO INITIATE A PHASE I CLINICAL TRIAL IN Q3 2018\nSource text for Eikon:\n (Gdynia Newsroom)\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T14:11:00.000+03:00", "crawled": "2018-05-04T16:33:55.009+03:00", "highlightTitle": ""}